View Clinical Trial (Medical Research Study)
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I - NCT01142700-32803(Clinical Trial 701426)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Orlando |
|
State:
|
|
FL |
| Zip Code: |
|
32803 |
| Conditions: |
|
Chronic Hepatitis C Virus Genotype 1 |
| Purpose: |
|
Based on 12-week on-treatment data, at least 1 dose of BMS-824393 can be identified which is
safe, well tolerated, and has sufficient antiviral activity to progress to late stage
clinical trials when combined with pegIFNα/RBV for treatment of chronically infected
hepatitis C virus genotype 1 treatment-naive subjects.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Treatment-naive subjects with genotype 1 chronic HCV
- HCV RNA ≥ 100,000 IU/mL at screening
- Seronegative for HIV and HBsAg
- Liver biopsy within prior 2 years demonstrating no cirrhosis
Exclusion Criteria:
- Any evidence of liver disease other than hepatitis C
- Diagnosed or suspected hepatocellular carcinoma
- Laboratory values: neutrophil count < 1500 cells/μL, platelet count < 90,000/μL;
Hemoglobin ≤ 12 g/dL (120g/L) for women and ≤ 13 g/dL (130 g/L) for men
- Cirrhosis |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 18, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|